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Summary 
Apoptosis is critically dependent on the presence of the ced-3 gene in Caenorhabditis elegans, 
which encodes a protein homologous to the mammalian interleukin (IL)-lfl-converting enzyme 
(ICE). Overexpression of ICE or ced-3 promotes apoptosis.  Cytotoxic T lymphocyte-mediated 
rapid apoptosis is induced by the proteases granzyme A and B. ICE and granzyme B share the 
rare substrate site of aspartic acid, after which amino acid cleavage of precursor IL-lfl (plL-lfl) 
occurs. Here we show that granzyme A, but not granzyme B, converts plL-lfl to its 17-kD 
mature form. Major cleavage occurs at Arg120, four amino acids downstream of the authentic 
processing site,  Asp116. IL-lfl generated by granzyme A  is biologically active.  When plL-lfl 
processing is monitored in lipopolysaccharide-activated macrophage target cells attacked by cytotoxic 
T  lymphocytes, intracellular conversion precedes lysis. Prior granzyme inactivation blocks this 
processing. We conclude that the apoptosis-inducing granzyme A  and ICE share at least  one 
downstream target substrate, i.e.,  plL-lfl.  This suggests that lymphocytes, by means of their 
own converting enzyme, could initiate a local inflammatory response independent of the presence 
of ICE. 
I 
L-13-converting enzyme (ICE) is a cytoplasmic cysteine 
protease characterized from cells of monocytic origin based 
on its ability to process the 31-kD inactive precursor of IL-1/~ 
(pIL-13) to the 17-kD proinflammatory cytokine IL-13 (1, 2). 
ICE is a member of a novel class of cysteine proteases with 
a unique (p20/p10)2  homodimeric structure (3,  4),  and it 
displays a rare sequence cleavage preference, i.e., after aspartic 
acids  (5,  6).  Activation  of human  plL-1B  occurs  at  the 
Aspl16-Alal,7 bond. 
Besides their role in the activation of pIL-1/3, ICE and its 
structural homologue, Nedd2 (7, 8), appear to be involved 
in the regulation of programmed cell death, or apoptosis. 
Overexpression of ICE or Nedd2 in rat fibroblasts or neurons 
induces cell death (7, 9). The CrmA protein, a viral serpin 
inhibitor of ICE, has been shown to prevent apoptotic cell 
death in neurons in vitro (10). Moreover, the expression of 
ced-3, a Caenorhabditis elegans protein belonging to the ICE 
family, is essential for programmed cell death to occur during 
worm development (11). 
The only other mammalian protease with aspase activity 
described until now is granzyme B, a serine protease expressed 
in granules of activated cytotoxic lymphocytes and NK cells 
(12). Along with granzyme A, a protease with trypsinlike 
specificity,  the pore-forming lytic perforin, and other con- 
stituents of the cytoplasmic granules, granzyme B is secreted 
into the intercellular space between killer and target cell upon 
specific cell-cell interaction (12). The physiological substrate(s) 
of granzyme A and B remain unknown, but the analysis of 
granzyme B (-/-)  mice points to a crucial role in the con- 
trol of apoptosis (13). DNA degradation in target cells lysed 
by lymphocytes deficient in granzyme B is impaired (13). In 
addition, granzymes A and B induce apoptotic cell death when 
added together with sublytic doses of perforin (14,  15). 
Since these two aspases occupy key regulatory roles in the 
induction of the apoptotic cell death program, the question 
of whether ICE and granzyme B share common substrates 
arose. We therefore investigated the possibility that the ICE 
substrate plL-lfl is processed by lymphocyte granzyme B. 
In spite of common substrate specificities, we show that only 
ICE produces active IL-lfl. However, granzyme A was found 
to be a potent IL-lfl-converting enzyme, suggesting that lym- 
phocytes are able to initiate an inflammatory reaction inde- 
pendent of ICE expression. 
Materials and Methods 
Reagents and Suhstrates.  Granzyme  A  substrate BLT (N-ol- 
benzyoxycarbonyl-t-Lys-thiobenzyl ester)  was  purchased  from 
Bachem (Bubendorf,  Switzerland),  and granzyme B  substrate 
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Products (Dublin, CA). The inhibitor for granzyme A (PhNHCO- 
NHCiTEtOIC, IGA) was a kind gift of Dr. J. Powers (Georgia 
Institute of Technology, Atlanta, GA), and the ICE inhibitor (Ac- 
Tyr-Val-Ala-Asp-CHO, YVA) was from the Glaxo Institute for Mo- 
lecular Biology (Geneva, Switzerland). DCI (3,4-dichloroisocou- 
marin) was purchased from Boehringer Mannheim (Mannheim, 
Germany). The polyclonal  goat antibody to mouse IL-13 was raised 
against purified  recombinant  protein. The rabbit antibody to human 
IL-13 was a kind gift from G. Mazzei (Glaxo Institute for Molec- 
ular Biology). The peptide corresponding to the human pIL-13 
sequence Ash110 to Asn123 was purchased from Bachem. 
Purification of  Proteases.  Granzymes  were purified  from granules 
of the B6.1 cytolytic T lymphocyte cell line as described (16). Ac- 
tive human ICE was isolated from the cytosol of the human mono- 
cytic cell line THP.1 as previously described (2). ICE was further 
purified by ion exchange  chromatography, sequentially  passing the 
cytosolic fraction over Q-Sepharose fast flow (Pharmacia LKB, 
Z~irich, Switzerland) followed by chromatography on an HR 10 
column (Mono-S; Pharmacia LKB). Briefly, the cytosolic fraction 
was dialyzed against 20 mM Hepes, pH 7.0, 5 mM EDTA, 2 mM 
dithiothreitol, 1 mM 4-(2-amino ethyl)-benzenesulfonyl  fluoride, 
0.1% CHAPS {3-[(3-cholamidopropyl)-dimethylammonio]-l-pro- 
panesulfonate},  and 15% ethylene  glycol (buffer  A), and passed over 
the Q-Sepharose equilibrated with buffer A. The column flow 
through  contained  ICE  activity  and  was  subsequently chro- 
matographed on Mono-S also equilibrated with buffer A. ICE ac- 
tivity was eluted with a 40-column volume linear gradient from 
0-0.5 M KC1 in buffer A. This represents a 76-fold purification 
of ICE  activity  and  sufficiently removed proteases capable of 
nonspecifically  hydrolyzing the ICE fluorescent substrate, Ac-Tyr- 
Val-Ala-Asp-7-amino-4-methyl  coumarin (Bachem). Using this sub- 
strate to assay  for ICE activity, Mono-S-purified ICE (0.5 mg/ml) 
had a specific activity of 0.12 nmol AMC min -1 mg -1. 
Enzymatic Activity Assays.  Granzyme A activity was measured 
using BLT as a substrate (17). Granzyme B activity was assayed 
as described for granzyme A, but BLT was replaced by BAT (18). 
For inhibition studies, the enzymes were preincubated at 20~  for 
30 min with the respective inhibitors at the following final con- 
centrations: 170 #M DCI, 70/zM IGA, and 2/xM YVA. 
Expression ofplL-l~.  In vitro transcription and translation of 
human pIL-13 was carried out with the TNT Coupled Reticulo- 
cyte Lysate System (Promega Corp., Madison, WI) according to 
the manufacturer's instructions. The human pIL-13 cDNA (Glaxo 
Research and Development,  Greenford, UK),  cloned into the 
pcDNA  I  Amp  expression vector (Invitrogen,  NV  Leek, The 
Netherlands) was transcribed using the T7 promoter. For processing, 
1/A of [3SS]methionine-labeled  pIL-13 was incubated with enzyme 
(0.2/zg granzyme A, granzyme B, or Mono-S-purified ICE) in 
a buffer containing 50 mM Tris-HC1, pH 8.0, and 1 mM CaC12 
for 10 h at 30~  (for digestion with ICE, 0.5 mM dithiothreitol 
was included). Inhibition of the enzymes  was performed  as described 
above. Reaction mixtures were analyzed by SDS-PAGE and sub- 
sequent autoradiography. Recombinant bacterial human pIL-13 
was kindly provided by P. Graber (Glaxo Institute for Molecular 
Biology). 
ILq BiologicalAssay.  Recombinant human pIL-13 (200 ng) was 
incubated with granzyme A (20 ng) during 4 h at 37~  and IL13 
activity was assayed as described (19). 
Amino Acid Sequencing and Matrix-assisted Laser Desorption Mass 
Spectroscopy.  Granzyme A-processed pIL-13 was separated  by SDS- 
PAGE, transferred to transblot membranes (Bio-Rad Laboratories, 
Ztirich, Switzerland) and subjected to amino acid sequence deter- 
mination using a pulsed liquid phase protein sequencer (477 A; 
Applied Biosystems,  Foster City, CA) on-line phenylthiohydantoin- 
amino-acid analyzer (120 A; Applied Biosystems). 
The peptide corresponding to the plbl/~ sequence Asn110 to 
Asn123 of human pIb13  (Bachem, 10/zg) was incubated with 
purified granzyme A or B (1/zg each) at 37~  for 16 h, and the 
cleavage site was determined by laser desorption mass spectroscopic 
analysis (20). 
Lysis  by  CTLs.  Bone  marrow-derived  macrophages from 
BALB/c mice (H2  d) were stimulated with LPS (10 ng/ml) for 3 h, 
washed, and then  added to  the Plasmodium falciparum circum- 
sporozoite protein peptide/H2 d specific CTL clone PbCSF12 (21). 
The effector to target cell ratio was 4:1. After 4 h, cells were cen- 
trifuged and the cell-associated  IL-1B  was determined by Western 
blot analysis  using a goat anti-mouse IL-13 polyclonal antiserum. 
Results 
As ICE and the lymphocyte granzymes are both crucial 
mediators of apoptosis,  we investigated whether these pro- 
teases  recognize  and cleave common  substrates.  Potential 
cleavage of in vitro-translated human pIL-13 by granzyme 
A or B was investigated. As expected, the 31-kD precursor 
form of IL-13 was efficiently  cleaved by ICE after a 10-h in- 
cubation into a fragment corresponding  to mature IL-13 (Fig. 
1 A). In spite of the shared substrate specificity of granzyme 
B and ICE,  no cleavage of plL-13 was observed  with the 
former enzyme. However, incubation with purified granzyme 
A generated a fragment similar in size to the authentic 17-kD 
IL-13. Cleavage  of plL-13 by granzyme A was rapid and 
already observed  after 30 rain (data not shown). The gran- 
zyme A-induced plL-13 conversion was completely blocked 
by serine protease inhibitor DCI, whereas the ICE inhibitor 
YVA was inactive (Fig. 1 A). In turn, ICE activity was com- 
pletely inhibited by YVA at identical concentrations (Fig. 1 A). 
E~cient cleavage of pIL-13 by granzyme A was also ob- 
served when recombinant human pIL-13 produced in bac- 
teria was used as a substrate (Fig. 1 B). Recombinant pIL-13 
gave rise to two bands at ,,o31 kD by Western blot analysis, 
which were converted to two species of 16-17 kD upon ad- 
dition of granzyme A. Both processed species showed an iden- 
tical NH2 terminus, indicating that the recombinant protein 
was degraded at its COOH terminus. The conversion  was 
again inhibited with DCI and IGA. Granzyme B had no effect 
on plL-1/3. 
ICE cleaves between Aspla6 and Ala117 of human plL-13 
to release the active cytokine. Sequence analysis of granzyme 
A-converted pIL-13 revealed Ser121 at its NH2 terminus, in- 
dicating that  plL-13  was  cleaved  after Argt20, in  perfect 
agreement with its thrombinlike activity (Fig. 2 A). Three 
minor contaminants were found with NH2 termini corre- 
sponding  to  Leu74, Ser133, and  Ala144. The  Arg~20-Ser121 
cleavage  site  was  also  obtained when a  synthetic peptide 
covering  the  ICE  pIL-13  cleavage  site  (NEAYVHDAP- 
VRSLN) was offered to granzyme A (Fig. 2 B). In spite of 
comparable esterolytic activity on their respective substrates 
(BLT and BAT), in no case was cleavage detected after the 
authentic Asp116 by granzyme B. 
1918  Processing  of Precursor Interleukin 13 by Granzyme  A Figure  1.  (A) Cleavage  of human pIL-13 by mouse  granzyme  A. 
[3sS]Methionine-labeled  pill3 was synthesized  in a rabbit reticulo- 
cyte  lysate  system  and incubated  with 200 ng of Mono-S-purified  ICE, 
granzyme  B (GB), and granzyme  A (GA), respectively.  Enzymes  were 
inhibited with the ICE inhibitor  YVA and the general serine esterase 
inhibitor  DCI, as indicated.  (B) Western  immunoblot  analysis  of  recom- 
binant human  plL-1B (200 ng) incubated  with GB (10 ng), GA (10 
ng), and GA that had been inactivated  with DCI and IGA. Incuba- 
tions were conducted for 4 h at 37~ 
We next asked whether this granzyme A-generated 17-kD 
fragment of IL-1/3 had any significant IL-1B biological ac- 
tivity. We have previously shown that, in an EL-4 T helper 
clone, EL-4-6.1, IL-2 receptor surface expression was strictly 
dependent on the presence  of picogram quantities of IL-1B 
(19). Precursor 31 kD  IL-I~ had no demonstrable activity 
in this assay (Table 1), as demonstrated by others previously 
(22).  Granzyme A  alone was also inactive.  FACS  |  analysis 
revealed induction of IL-2 receptor surface expression  only 
when plL-1B incubated with proteolytically  active granzyme 
A was added. Compared to the recombinant human IL-1B, 
the activity was approximately three- to fourfold lower. 
plL-1/3 is synthesized as a cytosolic protein without signal 
peptide. Although ICE is a cytoplasmic protein, processed 
plL-1/3 is not observed  to be associated with intact cells but 
is only generated and released when cells are undergoing apop- 
toffs (23). Only when rapid apoptosis of macrophages is in- 
duced by CTLs or ATP is intracellular conversion of plL-l~ 
observed (23). To evaluate whether this intraceUular processing 
is due to granzyme A, LPS-activated macrophages were used 
as targets for the cytolytic  T cells. The CTL clone used recog- 
nizes a peptide derived from the P.falciparum  protein circum- 
sporozoite in the context of the H2  d class I antigen. When 
the conversion ofplL-1B was analyzed in macrophages during 
CTL attack, the anti-IL-1B antibodies detected a faint, cell- 
associated band of 17 k.D in addition to the 31-kD precursor, 
thus confirming results by Hogquist et al. (23) showing that 
intracellular plL-1/3 cleavage was occurring during the cyto- 
lytic attack. Processed intracellular plL-1/3  was not present 
in cells not previously sensitized with the peptide (Fig. 3). 
When CTLs were pretreated for 30 min with IGA, intracel- 
lular processing of plL-1/3 was abolished, suggesting that gran- 
zyme A may be involved in the rapid conversion of plL-1B 
(Fig.  3). 
Discussion 
Our results show that, although both granzyme B and 
ICE exhibit aspase activity and are crucial mediators of apop- 
totic cell death, they do not act on identical cellular target 
proteins, plL-1/3, the only known substrate for ICE, is resis- 
tant to the proteolytic action of granzyme B. Even when the 
ICE pIL-1/3 cleavage site is offered as a 14-mer peptide, no 
cleavage after the critical Asp residue is observed.  These ob- 
servations  indicate that the presence of an Asp residue alone 
may not be solely sufficient  for the efficient  processing of 
plL-lB at the Aspn6-Valn7, and other structural constraints 
may be required. Today no proteinaceous substrate for gran- 
Figure  2.  NH2-terminal  sequence analysis  of the final  cleavage  product 
of recombinant  human  pIL-13  by granzyme  A. A minor  cleavage  site  (<5%) 
is indicated  with italic  letters. Also shown is the authentic  ICE cleavage 
site. (B) Cleavage  of a synthetic  peptide including  the region around  the 
cleavage site of human pIL-1B (Ash110 to Asn123) by granzyme  A. The 
cleavage site was determined  by laser desorption  mass spectroscopy.  The 
upper panel shows the analysis  of the peptide alone. In the lower panel, 
the peptide had been incubated  with granzyme  A. 
Table  1.  Activities  of IL-lfl 
Relative 
Sample  activity 
% 
Mature IL-1/3 (17 kD)  100 
plL-ll3  (31 kD)  <1 
pIL-l~ (31 kD)  + Granzyme A  30 
pIL-l~ (31 kD)  + Granzyme A  + DCI  <1 
pIL-1/3 (31 kD)  + Granzyme A  + IGA  <1 
+ Granzyme A  <1 
IL-1/3 activities  were determined  by the EL-4 assay  described previously 
(19). The obtained  activities  were normalized  to the activity  of recom- 
binant human IL-13, which was arbitrarily set to 100%. 
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cell interaction. Bone  marrow-derived  macrophages  were  stimulated  with 
LPS and incubated  with the CTL clone  PbCSF12,  which recognizes  a pep- 
tide on the surface  of H2d-bearing  target cells. Cells  were  centrifuged after 
a 4-h incubation and analyzed by Western blotting using an anti-mouse 
IL-l~-specific  antiserum. As indicated, CTLs  had been  pretreated  with gran- 
zyme A inhibitor (IGA).  2  Controls include target cells that had not been 
pulsed with the peptide and nonstimulated macrophages.  1 
zyme B has been found,  in spite of its known high estero- 
lytic activity on synthetic thioester  substrates.  The absence 
of plL-1B processing by granzyme B cannot exclude, how- 
ever,  the possibility that  other proteins,  such as those acti- 
vated during apoptosis, are substrates shared by ICE and gran- 
zyme B. 
Unlike granzyme B, the second lymphocyte protease gran- 
zyme A expressed in vivo can generate an active IL-I~ from 
the inactive precursor form. Cleavage occurs between Arg120 
and Ser121, yielding a cytokine four amino  acids  smaller in 
length than the one generated by ICE. Activity of the IL-I~/ 
diminishes rapidly as the cleavage  site moves away from the 
genuine Aspll6 cleavage site. Mast cell chymase and chymo- 
trypsin  generate molecules that  are two and three residues 
longer with no change in activity (24). Trypsin and elastase, 
in contrast,  generate polypeptides that are  13 and 41 amino 
residues longer than authentic IL-I~ but result in almost com- 
plete loss of activity (22). 
The biological activity of the granzyme A-processed pIL-1t5 
was decreased relative to the recombinant one, in agreement 
with  the reduction  of activity observed when Arg120 is re- 
moved or replaced by Asp (25), although  structure-activity 
studies with truncated proteins expressed in COS cells have 
shown that IL-1B retains full functional activity even when 
shortened to Met136 (26). By contrast,  using in vitro-trans- 
lated IL-1B, removal of Argl20  resulted in decreased receptor 
binding  (27). 
Precursor IL-1/3 is predominantly found in intact cells. In 
cells undergoing apoptosis, processing by ICE results in the 
release of the active cytokine, in contrast to necrosis,  in which 
IL-1B is released almost exclusively in the precursor form (23). 
Extracellular  proteases such as mast cell proteases may then 
be expected to cleave the 31-kD precursor IL-1B in areas of 
necrotic damage and thereby to release  substantial  amounts 
of IL-1B.  Intracellular  processing of plL-13,  however, has 
been observed in macrophages that are attacked by CTLs (23). 
CTLs cause rapid apoptosis induced by the action of gran- 
zyme B, granzyme A,  and Fas ligand,  a membrane protein 
with structural homology to TNF (15, 28, 29). Granzymes 
are believed to enter the target cell and act on intracellular 
substrates whose cleavage leads to apoptosis (30). This may 
account for the rapid intraceUular processing of pIL-1B. In- 
deed, treatment of CTLs with a granzyme A inhibitor abol- 
ished intracellular conversion ofplL-lfl in the target cell. Al- 
though  the granzyme  A  inhibitor  displays  high  specificity 
for granzyme A, it also blocks other proteases with similar 
specificity,  such as thrombin  (our own unpublished  data). 
Whether the absence of intracellular conversion is due to the 
inactivation of granzyme A or to other factors remains there- 
fore to be shown. 
This lymphocyte protease-generated  IL-113 is interesting 
from  the perspective that  some cells  known  to  synthesize 
plL-13 lack the corresponding converting enzyme (31). For 
example,  fibroblasts and keratinocytes have been shown to 
produce plL-13 mRNA but lack IL-13 cytokine activity (31, 
32). Other secreted proteases may also play a role in processing 
precursor IL-13.  Inflammatory responses of diverse origins 
may,  in  turn,  be a  consequence of this  process.  Mast  cell 
chymase generates an active cytokine and is proposed to play 
a critical role in the initiation  of the inflammatory response 
in the skin (31).  Cathepsin  G, which also displays  plL-13- 
converting activity, is present in synovial fluids and lung la- 
vage from patients with inflammatory polyarthritis  (32). A 
streptococcus-derived cysteine protease produces biologically 
active IL-I~/,  indicating  that  bacteria are  able to modulate 
the inflammatory response during pathogenesis  (33). The gran- 
zyme A-generated IL-lfl may directly contribute to the inflam- 
matory response in  areas  of lymphocyte tissue infiltration. 
IL-13 may recruit T  cells to the site of antigenic challenge 
caused by viruses and parasites and, in turn, activate Th lym- 
phocytes and CTLs whose effacient activation is dependent 
on the IL-13 costimulatory signal.  This would lead to mac- 
rophage and neutrophil sequestration to remove cellular mem- 
brane debris caused by CTL action.  In an effort to support 
this model,  others have attempted to identify the NH2 ter- 
minus of IL-13 at inflammatory sites to determine the pro- 
cessing site, but, because of the low concentration of IL-13 
present at inflammatory sites or as a result ofproteolytic degra- 
dation, they have been unsuccessful to date (32).  The obser- 
vation that precursor IL-I~ may be processed in vivo by pro- 
teases  other than  ICE may have  important  implications  in 
the future development of therapeutic approaches. In partic- 
ular,  drugs currently developed to inhibit  the plL-lfl pro- 
cessing in monocytes by interfering with ICE activity may 
be unable  to inhibit  IL-13 production  in vivo. 
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